Pharmaceutical Executive

Pharmaceutical Executive Podcast
  • 0,0 (0)
  • Levenswetenschappen
  • Wekelijks bijgewerkt

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

  1. Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics

    14 uur geleden

    Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics

    In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, Krista Pinto of Eversana argues that fully staffed pharma field teams are still missing revenue targets because the traditional deployment model itself needs to evolve, and EMA's CHMP issues a positive opinion recommending approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia across all lines of therapy in the European Union.

    4 min.
  2. Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

    4 dgn geleden

    Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

    Pharmaceutical Executive

    3 min.
  3. Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

    5 dgn geleden

    Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

    In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to advance targets selected by Lilly, building on a prior partnership between the two companies, Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on how the company's 3D printing technology enables real-time quality monitoring and rapid iteration to accelerate drug production, and life sciences industry advisor Partha Anbil examines the economics of the 340B Drug Pricing Program — including the forces driving its record $81.4 billion in 2024 purchases, the legal battles over manufacturer restrictions and rebate models, and what it all means strategically for pharmaceutical manufacturers in 2026.

    3 min.
  4. Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

    6 dgn geleden

    Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

    In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim its footing in global clinical research, market access expert Manasi Salgaonkar explains why Class of Trade classification is becoming one of the hardest — and most consequential — problems in pharmaceutical commercial operations, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on how DARPA's EQUIP-A-Pharma program is using federal investment to incentivize the reshoring of drug manufacturing to the United States.

    4 min.
  5. Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion

    22 jun

    Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion

    In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico Medicine enters an AI-powered drug discovery collaboration with SK Biopharmaceuticals valued at up to $2.5 billion to advance neuroimmune treatments in the central nervous system, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on the real-world benefits and persistent challenges of operating as a fully domestic manufacturer in an era of tariffs and supply chain pressure.

    3 min.
  6. Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

    19 jun

    Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

    In today's Pharmaceutical Executive Daily, an FDA advisory committee votes unanimously in favor of the benefit-risk profile of Moderna's investigational mRNA-1010 seasonal influenza vaccine across both younger and older adult populations, a pharma funding roundup covers Kardigan's upsized $400 million IPO debut on Nasdaq and cAMPfield Therapeutics' $180 million Series A launch, and Pharmaceutical Executive speaks with Brian Hilberdink of Boehringer Ingelheim on redefining what success looks like in obesity care in the GLP-1 era.

    4 min.
  7. Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive

    18 jun

    Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive

    In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biotech RayThera, FDA approves Utebzi as the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections, and FDA expands the indication for Merck's Capvaxive to include children and adolescents aged 2 through 17 with chronic medical conditions at increased risk for pneumococcal disease.

    4 min.
  8. Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs

    17 jun

    Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs

    In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu vaccine, a pharma roundup covers Merck's $510 million collaboration with Protillion Biosciences and Jazz Pharmaceuticals' multi-program antibody discovery deal with AbCellera, and Jack McFeely argues that behavioral and engagement insights are the missing ingredient in patient support programs that struggle to sustain long-term persistence.

    4 min.
Bekijk alles (387)

Info

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

Informatie

  • Maker
    Pharmaceutical Executive Podcast
  • Jaren actief
    2018 - 2026
  • Afleveringen
    387
  • Beoordeling
    Veilig
  • Website van aflevering
    Pharmaceutical Executive

Suggesties voor jou